

Supplementary Table I. Cross-cultural validation: characteristics of the patients and data of the questionnaires included in the analysis (n=268).

	All	HAs	LAs	<i>p</i> -value
No.	268	93	75	
Females, n (%)	201 (77)	64 (69)	137 (81)	0.025
Age, years (IQR)	57 (48-67)	55.5 (48-64.5)	58.0 (49-67.5)	0.177
Education level				0.121
Primary school, n (%)	29 (12)	9 (10)	9 (10)	
Middle school, n (%)	97 (39)	27 (30)	27 (30)	
Secondary school, n (%)	87 (35)	36 (40)	36 (40)	
University, n (%)	37 (15)	17 (19)	17 (19)	
Social status				0.76
Living with parents and family, n (%)	13 (6)	3 (5)	10 (7)	
Living alone, n (%)	30 (14)	8 (12)	22 (14)	
Living with partner and family, n (%)	159 (73)	47 (73)	112 (73)	
Other, n (%)	15 (7)	6 (9)	9 (6)	
Disease duration, years, median (IQR)	13.5 (8.8-19.3)	13 (8-20)	12.0 (6.8-20)	0.365
Item no. 1				
Answer no. 1, n (%)	112 (42)	28 (30)	84 (48)	<0.001
Answer no. 2, n (%)	83 (31)	18 (19)	65 (37)	
Answer no. 3, n (%)	32 (12)	18 (19)	14 (8)	
Answer no. 4, n (%)	41 (15)	29 (31)	12 (7)	
Item no. 2				
Answer no. 1, n (%)	113 (42)	0 (0)	113 (65)	<0.001
Answer no. 2, n (%)	79 (29)	24 (26)	55 (31)	
Answer no. 3, n (%)	39 (15)	32 (34)	7 (4)	
Answer no. 4, n (%)	37 (14)	37 (40)	0 (0)	
Item no. 3				
Answer no. 1, n (%)	128 (48)	21 (23)	107 (61)	<0.001
Answer no. 2, n (%)	78 (29)	25 (27)	53 (30)	
Answer no. 3, n (%)	25 (9)	15 (16)	10 (6)	
Answer no. 4, n (%)	37 (14)	32 (34)	5 (3)	
Item no. 4				
Answer no. 1, n (%)	139 (52)	24 (26)	115 (66)	<0.001
Answer no. 2, n (%)	65 (24)	20 (22)	45 (26)	
Answer no. 3, n (%)	27 (10)	21 (23)	6 (3)	
Answer no. 4, n (%)	37 (14)	28 (30)	9 (5)	
Item no. 5				
Answer no. 1, n (%)	117 (44)	13 (14)	104 (59)	<0.001
Answer no. 2, n (%)	86 (32)	31 (33)	55 (31)	
Answer no. 3, n (%)	30 (11)	19 (20)	11 (6)	
Answer no. 4, n (%)	35 (13)	30 (32)	5 (3)	

HAs: high adherers; LAs: low adherers; IQR: interquartile range.


Supplementary Table II.

Factors associated with high adherence to anti-rheumatic treatment defined by I-CQR5: multivariable regression analysis model including age.

	OR (95% C.I.)	<i>p</i> -value
Age (per 5-year increase)	0.91 (0.81-1.03)	0.127
bDMARD treatment	3.06 (1.45-6.46)	0.003
Patient-VAS (per 10-unit increase)	0.90 (0.80-1.02)	0.090
Model constant		0.872

OR: odds ratio; CI: confidence interval; DMARD: disease-modifying anti-rheumatic drug; bDMARD: biological DMARD; VAS: visual analogue scale.

Supplementary Fig. 1. Schematic enrolment of the patients in the study.



Supplementary Fig. 2. Validated Italian version of the 5-item Compliance Questionnaire for Rheumatology: Questionario sulla Compliance per la Reumatologia a 5 domande (I-CQR5).

To compute the result of the questionnaire refer to: Hughes LD, Done J, Young A: A 5-item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. *BMC Musculoskelet Disord* 2013; 14: 286.

Questionario sulla Compliance per la Reumatologia a 5 domande (I-CQR5)

Di seguito sono riportate delle affermazioni di pazienti affetti da una malattia reumatica. Indichi quanto è d'accordo con ciascuna cercando il numero che riflette maggiormente la Sua opinione.

1. Prendo i farmaci antireumatici perché in questo modo ho meno disturbi.

1	2	3	4
Completamente in disaccordo	In disaccordo	D'accordo	Completamente d'accordo

2. Non mi permetto mai di saltare la somministrazione dei farmaci.

1	2	3	4
Completamente in disaccordo	In disaccordo	D'accordo	Completamente d'accordo

3. Metto sempre le medicine nello stesso posto per non dimenticare di prenderle.

1	2	3	4
Completamente in disaccordo	In disaccordo	D'accordo	Completamente d'accordo

4. Prendo i farmaci prescritti perché ho completa fiducia Nel mio reumatologo.

1	2	3	4
Completamente in disaccordo	In disaccordo	D'accordo	Completamente d'accordo

5. Seguo sempre le indicazioni del mio medico.

1	2	3	4
Completamente in disaccordo	In disaccordo	D'accordo	Completamente d'accordo